Eli Lilly is striking a $1.9 billion gene-editing deal to develop inherited kidney disease treatments
Cris Tolomia
·
2026-06-03
·
via Quartz
The agreement gives Lilly exclusive rights to Ascidian's RNA exon-editing technology, which repairs faulty ge…
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。